What's Happening?
Eli Lilly's experimental weekly injection, retatrutide, has demonstrated significant efficacy in reducing the severity of obstructive sleep apnea (OSA) in adults with obesity, according to peer-reviewed trials published in The New England Journal of Medicine.
In non-diabetic participants with moderate-to-severe OSA, 51.6% of those receiving the 9-milligram dose achieved mild or no sleep apnea after 80 weeks, compared to 12.5% in the placebo group. The trials measured sleep apnea severity using the apnea-hypopnea index (AHI), which counts breathing interruptions per hour. Participants without diabetes started with an average AHI of 58.6 events per hour, and those on the 9-mg dose experienced approximately 34 fewer events per hour. After adjusting for placebo effects, the drug's added benefit was about 24 fewer events per hour. Participants with type 2 diabetes also showed improvement, though to a lesser extent, with a placebo-adjusted reduction of 14 to 15 fewer events per hour. The drug also led to reductions in hypoxic burden, a measure of oxygen level drops during sleep, and significant weight loss in participants.
Why It's Important?
The positive results from the retatrutide trials are significant for the millions of Americans suffering from obstructive sleep apnea, particularly those who struggle with or cannot tolerate continuous positive airway pressure (CPAP) therapy. Untreated sleep apnea is linked to serious health issues, including high blood pressure, heart rhythm problems, stroke, and increased risk of accidents due to daytime sleepiness. A new effective pharmaceutical option could offer a less intrusive and more accessible treatment for many patients. The drug's ability to also induce weight loss is a crucial benefit, as obesity is a major risk factor for OSA. This development could shift the treatment paradigm for sleep apnea, providing an alternative to mechanical devices and potentially improving patient adherence to therapy. However, it is important to note that retatrutide is not yet approved for any use, and direct comparisons with CPAP therapy have not been conducted.
What's Next?
Retatrutide is currently an investigational drug and cannot be legally sold to consumers. Eli Lilly will likely proceed with regulatory filings for FDA approval, which will involve a comprehensive review process. If approved, the drug's availability will depend on pricing decisions by Lilly and coverage determinations by insurance providers. Further research is needed to understand the long-term effects of retatrutide, including whether patients maintain benefits after discontinuing the drug and its efficacy in individuals without excess weight. Additionally, direct comparative trials against CPAP therapy would provide valuable insights into its place in the treatment landscape. Patients currently using CPAP should continue their prescribed therapy and consult with their sleep specialists regarding new treatment options like Zepbound, which is already FDA-approved for moderate-to-severe sleep apnea in adults with obesity.
Beyond the Headlines
The emergence of drugs like retatrutide and Zepbound represents a broader trend in medical innovation, moving towards pharmacological interventions for conditions traditionally managed by devices or lifestyle changes. This shift could have profound implications for healthcare delivery, patient quality of life, and the medical device industry. Ethical considerations around drug accessibility, cost, and potential side effects will become increasingly important as these treatments become more prevalent. The trials also highlight the complex interplay between obesity and sleep apnea, suggesting that treatments addressing underlying metabolic issues can have a significant impact on respiratory health during sleep. This could lead to more integrated approaches to managing chronic conditions, where a single treatment addresses multiple comorbidities. The potential for a pharmaceutical alternative to CPAP could also reduce the stigma associated with sleep apnea treatment for some individuals, encouraging more people to seek diagnosis and care.













